Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 May;30(3):166-178.
doi: 10.1097/ICU.0000000000000569.

Advances in dry eye disease treatment

Erin C O'Neil  1 , Matthew Henderson, Mina Massaro-Giordano, Vatinee Y Bunya
Affiliations
Review

Advances in dry eye disease treatment

Erin C O'Neil et al. Curr Opin Ophthalmol. 2019 May.

Abstract

Purpose of review: The prevalence and burden of dry eye disease continues to grow at a rapid pace, creating an increased need for new therapies. In a sector once limited to only a handful of treatments, clinicians now have multiple options available for patients who fail traditional therapies. This review summarizes the various treatment options available to clinicians treating complex dry eye disease patients.

Recent findings: As we better understand the multifactorial mechanisms leading to dry eye disease, treatments increasingly focus on the amelioration of the underlying deficiencies and inflammation, rather than on transient symptomatic relief alone. Most topical medications seek to replace deficient growth factors and/or decrease inflammation on the ocular surface. The majority of new devices and procedures seek to treat meibomian gland dysfunction, with one new device stimulating tear production through utilizing the nasolacrimal reflex pathway.

Summary: Clinicians have more options at their disposal in the treatment of dry eye disease than ever before, including topical medications and devices.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest

MMG: Celularity (consultant); Glaxo-Smith Kline (consultant); PRN Omega (personal financial interest)

ECO, MH: None

Figures

Figure 1:
Figure 1:
Application of Intense pulsed light (IPL)
Figure 2:
Figure 2:
Thermal pulsation system
Figure 3:
Figure 3:
MiBo ThermoFlo application device
Figure 4:
Figure 4:
TearCare iLid device
Figure 5:
Figure 5:
Intranasal Tear Neurostimulator
See this image and copyright information in PMC

References

    1. Farrand KF, Fridman M, Stillman IO, Schaumberg DA. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol 2017;182:90–98. - PubMed
    1. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care. 2008;14(3 Suppl):S102–106. - PubMed
    1. Dalzell MD. Dry eye: prevalence, utilization, and economic implications. Manag Care. 2003;12(12 Suppl):9–13. - PubMed
    1. Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. Curr Med Res Opin 2011;27(5):1041–1048. - PubMed
    1. Yu J, Asche CV, Fairchild CJ. The economic burden of dry eye disease in the United States: a decision tree analysis. Cornea 2011;30(4):379–387. - PubMed